Dr. Martin A. Wasserman

• 
  www.sec.gov/Archives/edgar/data/1107601/0000950144-04-0 - [Cached Version]
  Published on: 3/26/2004    Last Visited: 3/30/2004  

  Martin A. Wasserman, Ph.D.
  ...
  Martin A. Wasserman, Ph.D. has served as Senior Vice President of Discovery Research and Chief Scientific Officer since July 2003.He had previously served as Vice President of Discovery Research and Chief Scientific Officer since April 2001.Prior to joining AtheroGenics, Dr. Wasserman served as the Vice President and Senior Distinguished Scientist in the Respiratory and Rheumatoid Arthritis Disease Group within the U.S. Drug Innovation and Approval Organization (R,D) at Aventis Pharmaceuticals, Inc., from 1995 to 2001.He served as Director of Bronchopulmonary Research at Hoffmann-LaRoche, Inc. from 1992 to 1995.From 1989 to 1991, Dr. Wasserman served as Director of Biomedical Evaluation at the Bristol-Myers Squibb Pharmaceutical Research Institute.From 1981 to 1989, he served as Group Director of Pharmacology at GlaxoSmithKline.From 1972 to 1981, he was Research Scientist II at Pfizer (formerly The Upjohn Company).Dr. Wasserman has a B.S. in Pharmacy from The Ernest Mario School of Pharmacy at Rutgers University, and received an M.A. and Ph.D. in Pharmacology and Toxicology from the University of Texas Medical Branch, in Galveston, Texas, where he was honored with the Distinguished Alumnus Award in 1986.He is on the editorial boards of several journals and has published numerous articles in the areas of pulmonary, immunology, inflammation, cardiovascular, renal and gastrointestinal research.

• 
  www.sec.gov/Archives/edgar/data/1107601/0000950144-02-0 - [Cached Version]
  Published on: 3/11/2002    Last Visited: 6/27/2002  

  Martin A. Wasserman, Ph.D.
  ...
  Martin A. Wasserman, Ph.D.
  ...
  Martin A. Wasserman, Ph.D. joined AtheroGenics in April 2001 as Vice President of Discovery Research and Chief Scientific Officer.Prior to joining AtheroGenics, Dr. Wasserman was the Vice President and Senior Distinguished Scientist in the Respiratory and Rheumatoid Arthritis Disease Group within the U.S. Drug Innovation and Approval Organization (R,D) at Aventis Pharmaceuticals, Inc., from 1995 to 2001.He was Director of Bronchopulmonary Research at Hoffmann-LaRoche, Inc. from 1992 to 1995.From 1989 to 1991, Dr. Wasserman was Director of Biomedical Evaluation at the Bristol-Myers Squibb Pharmaceutical Research Institute.Dr. Wasserman has a B.S. in Pharmacy from Rutgers University College of Pharmacy, and received an M.A. and Ph.D. in Pharmacology and Toxicology from the University of Texas Medical Branch in addition to being honored with the Distinguished Alumus Award.He is on the editorial boards of several journals and has published numerous articles in the areas of pulmonary, immunology, inflammation, cardiovascular, renal and gastrointestinal research.

• 
  lion88.web.aplus.net/newsletter/Oct_Nov_2003.htm - [Cached Version]
  Published on: 10/1/2003    Last Visited: 9/3/2008  

  Only women ages 18 to 30 can participate in the current study, says Martin Wasserman of Glaxo-SmithKline, but we're hoping we'll eventually be able to test it in even younger women and be able to provide it to younger girls," he says.

• 
  AtheroGenics Announces Three Abstracts to Be Presented... - [Cached Version]
  Published on: 5/15/2003    Last Visited: 5/15/2003  

  "We are very pleased to have such a strong showing at this important meeting to highlight a potent new chemical series that could potentially have a major effect on the treatment of asthma," stated Martin A. Wasserman, Ph.D., Vice President of Discovery Research and Chief Scientific Officer for AtheroGenics.

• 
  AtheroGenics Press Release - [Cached Version]
  Published on: 7/9/2003    Last Visited: 5/10/2006  

  Atlanta, GA. - July 9, 2003 - AtheroGenics, Inc. (Nasdaq: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Martin A. Wasserman, Ph.D. has been promoted to Senior Vice President of Discovery Research.In this role, Dr. Wasserman will oversee all aspects of research, including medicinal chemistry, biology and pharmacology.Dr. Wasserman also serves as the Company's Chief Scientific Officer and he will continue to report to Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer.
  
  "Positioning Marty at the helm of our discovery research team gives us the opportunity to build on his expertise and leadership in support of our drug development efforts," said Medford.
  ...
  "Marty's detailed knowledge of pharmaceutical industry processes and his focus on discovery research technologies that facilitate the growth of the Company's product pipeline are invaluable assets to our therapeutic programs."
  
  Dr. Wasserman joined AtheroGenics in 2001 as Vice President of Discovery Research and Chief Scientific Officer.Prior to joining AtheroGenics, Dr. Wasserman's pharmaceutical experience spanned three decades.While at Aventis Pharmaceuticals, Inc. he served as Vice President and Senior Distinguished Scientist in the Respiratory and Rheumatoid Arthritis Disease Group.He also served as Director, Pulmonary Research, Department of Inflammation and Autoimmune Diseases at Hoffmann-LaRoche, Inc.Prior to joining Hoffman-LaRoche, Dr. Wasserman served as Group Director, Department of Pharmacology at SmithKline Beecham Corporation.
  
  Dr. Wasserman has a B.S. degree in Pharmacy from Rutgers University College of Pharmacy in New Jersey, and M.A. and Ph.D. degrees in Pharmacology and Toxicology from the University of Texas Medical Branch in Galveston, Texas, where he was also honored with the Distinguished Alumnus Award in 1986.

• 
  AtheroGenics loss widens - 2005-07-21 - [Cached Version]
  Published on: 7/21/2005    Last Visited: 7/21/2005  

  In other company news, Chief Scientific Officer Martin A Wasserman will retire on Aug. 1.

• 
  AutoModel™ and ProteoMine™ - [Cached Version]
  Published on: 10/14/2002    Last Visited: 7/3/2004  

  "We are pleased to be working with SBI, a company we consider to be a leader in structural proteomics and computational methodology," stated Martin Wasserman, Ph.D., Vice President of Discovery Research and Chief Scientific Officer of AtheroGenics.

• 
  Aventura News - Health News - Community Newspapers On... - [Cached Version]
  Published on: 10/5/2007    Last Visited: 10/5/2007  

  Next Generation executive officers include president Marshall Bronstein; vice presidents John Bussel, Wayne A. Cypen, Robert Rubin, Charles Sands and Martin Wasserman; secretary Andy Kane and treasurer Eli Tache.

• 
  BioExchange - Life Sciences and Biotechnology Resource... - [Cached Version]
  Published on: 10/14/2002    Last Visited: 11/5/2002  

  "We are pleased to be working with SBI, a company we consider to be a leader in structural proteomics and computational methodology," stated Martin Wasserman, Ph.D., Vice President of Discovery Research and Chief Scientific Officer of AtheroGenics."We view this collaboration as an opportunity to accelerate our research and discovery efforts to the nomination of clinical candidates."
  
  About SBI
  
  SBI is a privately-held proteomics-driven drug discovery company utilizing proprietary technologies for accelerating and optimizing the drug discovery process.SBI incorporates these technologies to advance its own drug pipeline, and concurrently markets them to pharmaceutical and to other drug discovery-focused biotech companies.

• 
  Bioscience Innovations -- Company Profile - [Cached Version]
  Published on: 2/5/2004    Last Visited: 7/8/2005  

  Martin A. Wasserman, Ph.D: senior vice president of discovery research and chief scientific officer.W.

Page:  1 2 3